# High Dose Intravitreal Ranibizumab for Recalcitrant Radiation Retinopathy

> **NCT01334879** · PHASE1 · COMPLETED · sponsor: **The New York Eye Cancer Center** · enrollment: 10 (actual)

## Conditions studied

- Radiation Retinopathy

## Interventions

- **DRUG:** ranibizumab 2.0 mg

## Key facts

- **NCT ID:** NCT01334879
- **Lead sponsor:** The New York Eye Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2014-10-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01334879

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01334879, "High Dose Intravitreal Ranibizumab for Recalcitrant Radiation Retinopathy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01334879. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*